Skip to content

Two Patterns of Micropulse Laser in the Treatment of Chronic Central Serous Chorioretinopathy

A Randomized Controlled Study of Two Patterns of Micropulse Laser in the Treatment of Chronic Central Serous Chorioretinopathy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05687422
Enrollment
50
Registered
2023-01-18
Start date
2023-02-01
Completion date
2023-12-31
Last updated
2023-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Serous Chorioretinopathy

Brief summary

Central serous chorioretinopathy (CSC) is a common eye disease mainly involving the macular area, causing central visual acuity loss. Recently, subthreshold micropulse laser used in treating chronic CSC is proved to be safe and effective. However, some studies indicate that it's less effective than half dose photodynamic therapy (PDT). Certain physicians, including us, think that this may be related to micropulse laser parameters. Thus we need to explore better laser patterns to replace PDT in treating chronic CSC. The aim of this study is to compare the treatment effect of two different patterns of laser parameters (small and regular spot diameter) in treating chronic CSC. In this randomized, double blinded, controlled trial, by comparing the subretinal fluid regression ratio, central retinal thickness, macular microvisual field, macular vascular density, chroidal volume changes and visual acuity of two groups 6 months after micropulse laser treatment, we aim to evaluate the safety and efficacy of refined micropulse laser in treating chronic CSC.

Interventions

PROCEDURE100μm laser spot diameter micropulse laser

100μm laser spot diameter micropulse laser at baseline, then follow-up for 6 months

PROCEDURE200μm laser spot diameter micropulse laser

200μm laser spot diameter micropulse laser at baseline, then follow-up for 6 months

Sponsors

Beijing Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Patients age range 18-50 years * Patients diagnosed with chronic Central serous chorioretinopathy * Patients have signed informed consent

Exclusion criteria

* A history of other fundus diseases or refractive media opacity * Patients have underwent other treatment methods for chronic Central serous chorioretinopathy * Diopter\>-6D * A history of system diseases such as hypertension or diabetes * A history of using local or systemic corticosteroids

Design outcomes

Primary

MeasureTime frameDescription
Subretinal fluid regression ratio6 monthsComparing the subretinal fluid regression ratio of two groups at 6 months follow-up
Central retinal thickness changes6 monthsComparing the central retinal thickness changes of two groups at 6 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026